Laboratory Corporation of America Holdings (NYSE:LH) : 17 analysts are covering Laboratory Corporation of America Holdings (NYSE:LH) and their average rating on the stock is 1.68, which is read as a Buy. 10 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Laboratory Corporation of America Holdings (NYSE:LH) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Laboratory Corporation of America Holdings (NYSE:LH) : The most positive equity analysts on Laboratory Corporation of America Holdings (NYSE:LH) expects the shares to touch $160, whereas, the least positive believes that the stock will trade at $125 in the short term. The company is covered by 14 Wall Street Brokerage Firms. The average price target for shares are $141.5 with an expected fluctuation of $10.26 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Also, In a research note released to the investors, Barclays maintains its rating on Laboratory Corporation of America Holdings (NYSE:LH).The analysts at the brokerage house have a current rating of Overweight on the shares. In a recent information released to the investors, Barclays raises the new price target from $152 per share to $155 per share. The rating by the firm was issued on April 26, 2016.
Laboratory Corporation of America Holdings (NYSE:LH): stock turned positive on Tuesday. Though the stock opened at $126.79, the bulls momentum made the stock top out at $127.05 level for the day. The stock recorded a low of $125.71 and closed the trading day at $126.47, in the green by 0.75%. The total traded volume for the day was 1,291,084. The stock had closed at $125.53 in the previous days trading.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (President & CEO) of Laboratory Corp Of America Holdings, King David P had sold 196,400 shares worth of $25,221,688 in a transaction dated June 13, 2016. In this transaction, 196,400 shares were sold at $128.42 per share.
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment, which includes core testing, as well as genomic and esoteric testing; and the Other segment, which consists of the Companys non-United States clinical diagnostic laboratory operations in Ontario, Canada. It also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, womens health, cardiovascular disease, identity, forensics, infectious disease, endocrinology, oncology, coagulation, occupational testing and pain management.